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  ABSTRAK 
 
Kajian Penilaian Semula Modified Rapid Monoclonal Antibody Immobilization of Platelet 
Antigen (MR-MAIPA) Dalam Mengesan Antibodi Terhadap Platelet Di Kalangan 
Pesakit Pesakit Yang Di Suspek Mengalami Immune Thrombocytopenia 
 
Pengenalan. Ujian antibodi terhadap platelet di Malaysia hanya dijalankan di Pusat Darah Negara 
(PDN), Kuala Lumpur. Sebelum tahun 2013, ujian antibodi terhadap platelet di Malaysia dijalankan 
menggunakan teknik MAIPA. Namun begitu, MAIPA memerlukan masa selama tiga hari untuk setiap 
ujian dijalankan. Ini menyebabkan kelewatan dalam mengenal pasti antibodi terhadap platelet 
sekaligus boleh menyebabkan doktor yang merawat pesakit mengalami sedikit kesukaran dalam 
merawat pesakit. Oleh itu, sejak Julai 2013, Pusat Darah Negara telah menggunakan MR-MAIPA 
untuk menjalankan ujian mengenal pasti antibodi terhadap platelet. Semenjak pelaksanaan MR-
MAIPA, tiada penilaian semula mengenai teknik ini. 
 Kajian ini bertujuan menilai semula MAIPA dan MR-MAIPA dalam megesan antibodi tehadap 
platelet.  
  
Kaedah. Kajian ini dijalankan secara propektif di mana semua sampel yang dihantar ke Pusat Darah 
Negara untuk identifikasi antibodi platelet, bermula 1 Jun 2015 sehingga 30 November 2015 telah 
diambil untuk kajian. Proses identifikasi antibodi platelet bagi sampel tersebut dijalankan 
menggunakan MAIPA dan MR-MAIPA secara serentak. Untuk MR-MAIPA, ujian tambahan 
dijalankan dengan pentitratan kawalan positif (sehingga pencairan 1:256) untuk meniliai had 
sensitiviti MR-MAIPA. Kesemua data yang didapati dari kajian ini akan dianalisa untuk sensitiviti, 
kekhususan, Nilai Ramalan Positif (Positive Predictive Value) dan Nilai Ramalan Negatif (Negatif 
Predictive Value). 
 
xi 
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Keputusan. Terdapat 40 sampel dari 40 pesakit yang berlainan terlibat dalam ujian penilaiaan MR-
MAIPA dan MAIPA. Dari 40 sampel tersebut, 77.5 peratus adalah negatif untuk antibodi terhadap 
platelet dan hanya 22.5 peratus sahaja adalah positif untuk antibodi terhadap platelet, untuk kedua-dua 
ujian tersebut,. Sensitiviti, spesifisiti, Nilai Ramalan Positif (Positive Predictive Value) dan Nilai 
Ramalan Negatif (Negatif Predictive Value) MR-MAIPA adalah setara dengan MAIPA. Untuk 
sensitiviti MR-MAIPA, ia mampu mengesan Anti HPA-1a dan Anti HLA-1 sehingga pencairan 
1:256. Bagi Anti HPA-3a, MR-MAIPA hanya mampu mengesan sehingga pencairan 1:8. 
 
Kesimpulan. MR-MAIPA adalah setara dengan MR-MAIPA dalam mengenal pasti antibodi terhadap 
platelet. Namun begitu, MR-MAIPA mempunyai kelebihan dari segi tempoh masa ujian iaitu 5 jam 
berbanding MAIPA yang 8 jam. Oleh itu, MR-MAIPA sesuai digunakan sebagai ujian mengenal pasti 
antibodi terhadap platelet. Namun begitu, platelet panel yang digunakan oleh kedua-dua teknik harus 
dipantau dengan kerap untuk memastikan kejituan teknik ini dalam mengesan antibodi terhadap 
platelet.     
 
Kata kunci: MAIPA, MR-MAIPA, Pusat Darah Negara  
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ABSTRACT 
Re-evaluation of Modified Rapid Monoclonal Antibody Immobilization of Platelet Antigen 
(MR-MAIPA) For Detecting Platelet Antibody In Patient With Suspected Immune 
Thrombocytopenia 
 
Introduction. Platelet antibody identification test in Malaysia is solely run by the National Blood 
Centre, Kuala Lumpur (NBCKL). Before 2013, the antibody identification test was using Monoclonal 
Antibody Immobilization of Platelet Antigen (MAIPA). However, MAIPA needs three days to 
complete the test. This may cause delay in detecting platelet reactive antibody, hence some 
inconveniences for clinician in treating their patients. Therefore, since July 2013, NBCKL had been 
utilizing MR-MAIPA for identifying platelet reactive antibody. Since MR-MAIPA implementation, 
no further re-evaluation of the method had been done.  
This study aims to evaluate MAIPA and MR-MAIPA in detecting the platelet antibody in NBCKL. 
 
Methods. A prospective study was conducted in which all samples sent to NBCKL from 1st June 
2015 - 30th November 2015 for platelet antibody identification was included in the study. The sample 
is run both using MAIPA and MR-MAIPA concurrently. For MR-MAIPA, further evaluation was 
carried out, a titration of positive control (up to 1:256 dilution) was titrated to evaluate sensitivity of 
MR-MAIPA. All the data collected was analyze for specificity, sensitivity, Positive Predictive Value 
(PPV) and Negative Predictive Value (NPV). 
Results. There were 40 samples from 40 different patients. Out of the 40 samples, 77.5% were 
negative for platelet reactive antibody and only 22.5% were positive for platelet reactive antibody, for 
both MR-MAIPA and MAIPA. The sensitivity, specificity, PPV and NPV of MR-MAIPA were 
comparable with MAIPA. For sensitivity, the MR-MAIPA was able to detect Anti-HPA 1a and Anti-
HLA 1 up to dilution of 1:256. For Anti-HPA- 3a, MR-MAIPA was able to detect up to 1:8 dilution. 
xiii 
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Conclusions. The MR-MAIPA had equivalent sensitivity as MAIPA in detecting platelet reactive 
antibody. The MR-MAIPA has the advantage of completing the test within 5 hours to MAIPA that 
needs 8 hours to complete the test. The MR-MAIPA performance is suitable to be used for platelet 
antibody identification. However, the platelet panel used in both method need to be regularly 
monitored to ensure the test is precise in detecting platelet antibodies. 
 
 
Key words: MAIPA, MR-MAIPA, National Blood Centre, Kuala Lumpur (NBCKL) 
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CHAPTER 1 
INTRODUCTION 
1.1 Overview of platelet serology service in Malaysia 
 The Platelet serology Unit, under Immunohematology Department, National Blood 
Centre Kuala Lumpur (NBCKL) was first established in 1999. The tests offered were platelet 
antibody screening, platelet antibody identification and platelet cross matching. Investigation 
to diagnose patient with thrombocytopenia: from Neonatal Alloimmune Thrombocytopenia 
(NAIT), Idiopathic Thrombocytopenic Purpura (ITP) and Platelet Refractoriness would 
benefit from these tests. The request for platelet antibody identification had been steadily 
increased every year. This increment is demonstrated by the accumulative number of sample 
per year – 89 samples in 2012 to 101 samples in 2014. The factors contributing to the 
increment are due to increased number of patients, improvement in the current health 
facilities and increased awareness of the clinician on such conditions and diagnoses. 
 Few methods of platelet antibody detection were introduce and used: Immucor 
Capture P
®
, Solid Phase Red Cell Adherence with Frozen Platelets (SPRCA-F) and 
Monoclonal Antibody Immobilization of Platelet Antigen (MAIPA). MAIPA has been 
identified as the gold standard. Despite been identified as the gold standard, it has few 
limitations that can influence the management of patient. 
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1.2  Overview of MAIPA and MR-MAIPA 
 Several techniques had been used worldwide for platelet antibody identification. 
There were techniques that involving stripping of HLA antigen from platelet using 
chloroquine pre-treatment, solid phase radio immune assay and Western blot procedure. 
However, each of these techniques has its disadvantages such as indirect detection of platelet 
reactive antibody, destroying HLA antigen and insensitiveness in detecting the antibody. In 
1987, Kiefel and colleague had made a discovery in platelet antibody identification 
technique. It was an enzyme immunoassay that utilizes highly platelet-specific monoclonal 
antibody. It was a superior and sensitive tool for detailed analysis of sera with ambiguous 
serological findings. The technique was named as Monoclonal Antibody Immobilization of 
Platelet Antigen, or better known as MAIPA (Kiefel et al., 1987). For the next 20 years, 
MAIPA became a gold standard for platelet antibody identification. 
 Although MAIPA is the gold standard in platelet antibody identification, the test was 
time consuming, causing a major concern. These may cause diagnostic delay, thus in 2007 a 
group of researchers had made a modification to the MAIPA technique. Campbell et al. 
found that MAIPA took approximately 8 hours to complete a single test and substantial 
variations in its protocol, which is causing interlaboratory differences in specificity and 
sensitivity, needs to be addressed. A new technique should be faster and at least equivalent as 
the original MAIPA in term of sensitivity and specificity in platelet antibody identification 
needs to be developed. Campbell et al. made a modification to the original MAIPA, which 
resulted in an assay that is much faster without losing its sensitivity. The technique is 
described as Modified Rapid Monoclonal Antibody-Specific Immobilization of Platelet 
Antigen, or better known as MR-MAIPA. This method can be done within 5 hours compared 
to MAIPA which took 8 hours, without loss of sensitivity. With this improvement, diagnosis 
can be made faster, and patient can receive better treatment (Campbell et al., 2007) 
3 
 
1.3  Rational justification of the study  
 MR-MAIPA has been evaluated and compared before. Only the evaluation was not 
done in NBCKL. No correlation had been done in evaluating MR-MAIPA against MAIPA in 
detecting platelet antibody identification. A good correlation finding is a value in quality 
assurance of a test. 
 
1.4 Objectives  
 1.4.1 General Objective 
 To evaluate the effectiveness of MR-MAIPA and MAIPA in platelet antibody 
identification. 
 1.4.2 Specific Objectives 
i. To investigate the limit of sensitivity of MR-MAIPA in platelet antibody  
identification. 
  ii. To evaluate the performance of MAIPA and MR-MAIPA 
iii. To describe the antibodies detected by MAIPA and MR-MAIPA.  
1.5 Research Hypothesis 
 1.5.1 Alternative Hypothesis 
MR-MAIPA technique is equivalent or superior to reference method/gold standard 
MAIPA in platelet antibody identification. 
1.5.2 Null Hypothesis 
MR-MAIPA is less superior then MAIPA in detecting platelet antibody. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Platelet overview 
 Platelet is an important part of haemostasis. Early of its discovery, it was merely 
known as dust of the blood. Started in the bone marrow, platelets are form from the 
fragmentation of the mature megakaryocytes
 
(Kaushansky, 2008).  
 Mature platelet is anucleate, with a discoid shape and a dimension of approximately 
3.0 x 0.5um. Since the platelet has no nucleus, the lifespan of the platelet is short with 
duration of 9 to 10 days (Hanson SR - Slichter, 1985). It has four main storage granules 
which are the dense granules, α-granules, peroxisomes and lysosomes. The dense granules 
and the α-granules content are important in supporting haemostasis. The dense granule 
contains high level of ADP, ATP, Serotonin and Ca2+. The α-granules on the other hand 
contain the Fibrinogen, Von Willebrand Factor (vWF), Factor V, Plasminogen, PAI-1, α2-
antiplasmin and much more (Watson and Harrison, 2010).  
 In an injury, where there is bleeding, the platelet would first form the platelet plug, 
which later followed by coagulation process. The traditional thoughts of coagulation would 
involve the intrinsic and extrinsic pathway of coagulation factors. However, with the cell 
based theory of coagulation, it was shown that coagulation is not just about cascade of 
coagulation factors. Platelet also plays an important role in haemostatic activation. It serves 
as a stage for the coagulation factors to react on the surface. In summary, in the cell based 
theory, there are three main phases towards coagulation, namely, initiation, amplification and 
propagation phase. In initiation phase, exposed Tissue Factor (TF) from injury vessel to the 
flowing blood resulted in generation of small amount of Factor IXa and thrombin. This brings 
to the second phase, which is amplification phase, where these small amounts of thrombin 
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will then activates the platelets, which releases vWF and leads to formation of Factor Va, 
Factor VIIIa and Factor Xia. In the final phase, Propagation phase, those various activated 
coagulant factors that generated in earlier phase, assemble on the activated platelet to form 
tenase complex, leading to Factor Xa generation. Later, the prothrombinase complex forms, 
resulting in burst of thrombin generation (Smith, 2009). 
 Human platelets express blood group antigen (eg: ABO, I, P), CD 36, HLA-1, GP VI 
and its own antigen, the Human Platelet Antigen-HPA (Cooling, 2007; Wu, 2014). Until 
now, there are 34 HPA have been identified which are expressed on 6 different glycoproteins. 
The antigen expression varies from ethnics and populations (Wu, 2014). The variety of HPA 
may lead to alloimmunization, especially if the recipient has antigen negative towards the 
donor antigen. The pathophysiology of platelet alloimmunization is also the same in the case 
of Foetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), where the mother 
developed antibody towards the foetal and neonatal platelet (Koh et al., 2012; Bertrand and 
Kaplan, 2014). Other conditions that have the same principle as above is Post Transfusion 
Purpura (PTP) and post transfusion platelet refractoriness (Norton et al., 2004; Keashen-
Schnell, 2007).   
 
2.2  Immune Thrombocytopenia 
  In any immune thrombocytopenia, such as Neonatal Alloimmune Thrombocytopenia 
(NAIT), Post Transfusion Purpura (PTP), platelet transfusion refractoriness or Immune 
Thrombocytopenic Purpura (ITP), they share a common cause, platelet-reactive antibodies 
(Metcalfe, 2004; Sandler, 2004; Sathar, 2006; Keashen-Schnell, 2007; Bertrand and Kaplan, 
2014).  
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2.2.1 Neonatal Alloimmune Thrombocytopenia (NAIT) 
 The pathophysiology of NAIT is when maternal develops antibody toward foetal 
platelet antigen which the foetal inherited from the paternal side. NAIT may cause severe 
bleeding for the foetus and also subsequent pregnancies if the foetal poses the platelet antigen 
which the mother had develop antibody against it (Williamson et al., 1998; Kaplan, 2007). 
The NAIT can manifest from petechial up to intracranial haemorrhage. NAIT can occur as 
early 20-24 weeks of gestation (Williamson et al., 1998). The severity of NAIT may differ 
among anti HPA. Anti HPA-1a and Anti HPA-3a is usually associated with severe NAIT 
while Anti HPA-5b is less severe than Anti HPA-1a (Kaplan, 2007). The prevalence of NAIT 
is around 1 in 800-1000 neonates (Bertrand, 2014). Some journal would quote the prevalence 
is 1 in 1000-2000 live births (Hacene Brouk, 2015). Other study would quote up to 1 in 1000-
5000 (Ng Khuen Foong, 2011). In 2011, there was a case report in Malaysia regarding NAIT 
which demonstrate the maternal platelet reactive antibody against paternal platelet antigen 
inherited by the foetal. In the paper, it was mentioned that Anti HPA-1a is the cause of the 
NAIT (Ng Khuen Foong, 2011). In 2015, another paper demonstrate of Anti HPA-1a in 
Malaysia (M. I. Armawai, 2015).  Anti HPA-1a is more common cause of NAIT in 
Caucasian rather than Asian. Anti HPA-4b is much more common in East Asian (Nadarajan, 
2014). Therefore, the finding of Anti HPA-1a as the cause of NAIT in these two cases in 
Malaysia is a rare finding. Since Anti HPA-1a is more common in Caucasian, some European 
country (eg: Norway), carried out routine investigation for maternal Anti HPA-1a antibody 
level as a potential predictor of alloimmune thrombocytopenia in the newborn (Killie et al., 
2008)  
 In the treatment of NAIT, ideally, antigen negative platelet towards the detected 
platelet alloantibody detected should be given to the neonate. Therefore, the platelet from the 
mother of the affected neonate may be used for the treatment. If, these platelet are use, it 
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should be washed to remove the platelet alloantibody and irradiated to prevent Transfusion 
Associated Graft Versus Host Disease (Bertrand and Kaplan, 2014; Hacene Brouk, 2015). 
However, this might not be available due to some constraints, therefore, registry of HPA 
typed donor had been developed in some countries, to find compatible platelet. Some 
country, such as France, even used frozen platelet for treatment modality. However, in 
emergency situation, a random platelet can be used with addition of IVIG to limit its 
destruction (Sachs, 2013; Bertrand and Kaplan, 2014; Hacene Brouk, 2015). In one case 
reporting, it had shown successful transfusion of incompatible donor platelets in NAIT case. 
The transfusion of incompatible donor platelet was due to delay in MAIPA reporting for the 
patient (Schallmoser et al., 2006). 
 
2.2.2 Immune Thrombocytopenic Purpura (ITP) 
 ITP is an autoimmune disorder in which there is a persistent thrombocytopenia 
(typically platelet count is less than 150 x109/L). It can affect adults and also children 
(Norton et al., 2004; Sathar, 2006). The prevalence of the disease ranges from 4-5.3 in 
100000 in children. In the US, the incidence ranges from 5.8-6.6 in 100000 populations 
(Force, 2003; Sathar, 2006). In ITP, there is no specific or gold standard test to diagnose it. It 
is a diagnosis by exclusion. Identifying specific platelet antibody might not be useful. 
However, it may have some values to distinguish immune from non-immune 
thrombocytopenia in difficult cases (eg: combination of bone marrow failure associated with 
immune-mediated thrombocytopenia). Recently, there are studies regarding prediction of 
chronic ITP and risk of bleeding. These studies found that ITP patients with antibody 
detected through MAIPA may have a risk of bleeding and chronic course of the disease 
compared to those that have no antibody detected (Grimaldi D, 2014).  Patients with platelet 
count more than 30x10
9
 /L may not need any treatment. Treatment is only started if patient is 
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symptomatic and platelet count below 30x10
9
 /L. The main objective of the treatment is to 
reduce the destruction of platelets. The strategies of treatment are divided to First Line and 
Second Line of treatment. First line treatment is usually involving administering 
Corticosteroid and IVIG. Second line of treatment involves surgical intervention, 
splenectomy and medications (eg: Danazol, Azathioprine, Dapsone and Anti –D). For 
Refractory ITP, multi drugs combination (eg: Vinca alkaloid, Rituximab, IVIG) and 
eradication of Helicobacter Pylori infection are made to achieve platelet count more than 
30x10
9
 /L.  Platelet is transfused if there is severe haemorrhage or reached critical value (< 10 
x 10
9
L) (Sandler, 2001; Force, 2003; Sathar, 2006). Recently, there are studies involving 
Thrombopoietin (TPO) Receptor Agonist in treating ITP. The outcomes looks promising as 
patient on the treatment had sustained increased in platelet counts (Gernsheimer, 2009; 
Provan and Newland, 2015; Rodeghiero and Ruggeri, 2015) 
 
2.2.3 Post Transfusion Platelet Refractoriness 
 The Trial to Reduce Alloimmunization to Platelets (TRAP) study defined post 
transfusion refractoriness as increment of less than 5 × 10
9
/L of Corrected Count Increment 
(CCI) within 1 hour post platelet transfusion on two sequential occasions. This condition may 
be due to immune or non-immune causes. For immune causes, it is usually due to HLA 
alloimmunization. However, HPA alloimmunization can also contribute to the cause (Norton 
et al., 2004; Simon J. Stanworth, 2015). This condition is usually seen in patients who 
received regular platelet transfusion. 
 In managing Post Transfusion Platelet Refractoriness case, the cause of refractoriness 
should be investigated and managed accordingly to the underlying cause. If the cause is due 
to alloimmunization, an antigen negative platelet should be given to the patient. Other than 
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that, leukoreduction of blood components may decrease the incident of platelet refractoriness 
and HLA alloimmunization (Slichter, 1997; Norton et al., 2004; Basire and Picard, 2014) 
 
2.2.4 Post Transfusion Purpura 
 Post transfusion purpura is defined as severe thrombocytopenia (platelet count < 10 × 
10
9
/L) that occurs 5 to 12 days post blood transfusion.  A classic presentation would usually 
involve older, multiparous woman with antibody-mediated drop in platelet after 7 to 10 days 
after transfusion (Keashen-Schnell, 2007; Mikhail Menis, 2015). It is a rare condition. The 
Serious Hazard of Transfusion (SHOT) study in the United Kingdom reported the incidence 
of 1 in 465000 transfusions. Post Transfusion Purpura is usually associated with anti HPA. 
Treatment of choice would involve giving IVIG with platelet transfusion with a good  rapid 
response may be expected in 85% of cases (Norton et al., 2004). 
 
2.3  Human Platelet Antigen (HPA) and related platelet antibody 
 Apart from ABO antigen, the platelet also has its own antigen, known as Human 
Platelet Antigen (HPA). Until today, there are 34 specific platelet alloantigens (HPA 1 to 
28bw) had been found (Li et al., 2014). The variety of HPA and its differences from one 
population to another population pose a possibility of alloimmunization (Kaplan, 2007; 
Nadarajan, 2014).  One of the earliest HPA identified was HPA 1a/1b. It was found in 1956-
1957, when a patient develop thrombocytopenia post transfusion (later, it known as post 
transfusion purpura) (Aster and Newman, 2007). In the Western population, anti HPA 1a is 
the common cause of NAIT. However, it is rare in the East Asian population. Instead, anti 
HPA 4b is more common in NAIT cases in East Asian population (Nadarajan, 2014). 
Although anti HPA 4b is commonly associated with NAIT in the East Asian population, there 
is still possibility of other rare anti HPA that may cause NAIT. Two of such case had been 
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reported in Japan, NAIT cases involving anti HPA 21bw (Koh et al., 2012). However, recent 
study had shown that alloantibodies against low frequency HPA do not account for a 
significant proportion of NAIT (Santoso and Tsuno, 2015).  
 As variety of HPA among location and population, a platelet donor registry should be 
established in each country. This is to provide match platelet to the patients when the need 
arise (Feng et al., 2006; Tan et al., 2012).   
 
2.4  Platelet Donor Registry  
 Platelet alloimmunization may cause much problem (Norton et al., 2004) for the 
patient and the treating physician. The best platelet to be given to a patient who had 
alloantibody towards platelet is to provide antigen negative platelet (Norton et al., 2004; 
Bertrand and Kaplan, 2014; Katus et al., 2014). In doing that, two most important 
components that must work in tandem are the platelet registry and platelet antibody 
identification. It would be a long arduous task if only one of the components exists and the 
patient needs the specific platelet transfusion. The data of platelet antigen varies from each 
region or even country. In almost homogenous population (eg: Japan), it may have different 
HPA compared to a multi ethnic country (eg: Malaysia). Therefore, each country must 
develop their own data of platelet registry (Feng et al., 2006; Tan et al., 2012; Li et al., 2014; 
Nadarajan, 2014; Wu, 2014). Platelet antibody detection should also be utilised efficiently in 
treating immune causes thrombocytopenia. The development MR-MAIPA had gave a better 
and faster outcome in detecting platelet antibody (Kiefel, 1992; Campbell et al., 2007; 
Kaplan et al., 2007). Utilising both platelet donor registry and platelet antibody detection 
would lead a better outcome in treating immune mediated thrombocytopenia (Nance et al., 
2004). 
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2.5 Platelet Antibody Identification 
 Platelet antibody identification is important in management of immune 
thrombocytopenia. In 1987, a study was published on a new technique in platelet antibody 
identification. It was known as MAIPA. MAIPA had overcome other technical difficulties in 
platelet antibody identification. The technique based on capturing the trimetric complex 
(Monoclonal antibody specific to platelet Glycoprotein-Platelet Antigen-Investigated platelet 
antibody). It is a simple test without needing any sophisticated equipment. However, the test 
required 8 hours to completed (Kiefel et al., 1987). As the cornerstone of the test is capturing 
the trimetric complex, the original MAIPA protocol had undergone some modification across 
the globe. The modifications include the monoclonal antibody used and even the procedure 
protocol. These variations may cause significant differences in ability to detect antibody level  
and even the sensitivity of the test itself (Killie MK, 2010). In 2007, a modification to 
MAIPA which makes it rapid without losing its sensitivity in detecting platelet antibody was 
discovered. The modifications involved using of smaller sample requirement (investigated 
serum), reagents and incubation period. It provides a better alternative to the original MAIPA 
as it can be done much faster, within 5 hours (Campbell et al., 2007) 
 Although MAIPA had been a gold standard in platelet antibody identification, it has 
some limitations. For example, the selection of monoclonal antibody for MAIPA may cause 
competition in binding for the same antigen site as the investigated antibody, resulting in 
inability to identify the investigated antibody (Tomoya Hayashi and Hirayama, 2015). The 
preparation of platelet panel, may cause destruction of certain HPA, which may lead to false 
negative results. In terms of procedure, certain low avidity antibody may be dissociated 
during wash procedure, also contributing false negative results (Santoso and Tsuno, 2015). 
Therefore, it is important for a diagnostic lab not to rely on a single technique in their facility 
to facilitate in investigation of platelet antibody. Recently, a study using flow cytometry 
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method in detecting platelet antibody had shown 93% concordance with MAIPA finding. It 
can be done much faster, within 3 hours, with a very small sample of investigated serum 
needed (10L of the investigated serum) compared to MAIPA (Leendert Porcelijn, 2013; 
Santoso and Tsuno, 2015). Another paper had also shown this flow cytometry based method 
is also recommended for detection autoantibodies in ITP patients (Yunxiao Zhao et al., 
2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
CHAPTER 3 
Methodology 
 
3.1 Study Venue 
 The National Blood Centre Kuala Lumpur serves as the only platelet reactive 
antibody identification and platelet cross matching centre in Malaysia. It receives request for 
platelet reactive antibody identification and platelet cross matching from the government 
hospitals as well as the private health centres.  
 
3.2 Study Duration 
The study duration is from 1
st
 June 2015 – 30th November 2015. 
 
3.3 Inclusion Criteria and Exclusion Criteria 
3.3.1  Inclusion Criteria 
i. All samples for platelet antibody identification received within the study period (1
st
 
June 2015 - 30
th
 November 2015). 
3.3.2 Exclusion Criteria 
i. All rejected samples by NBCKL (eg: lyse sample, insufficient sample, samples in 
wrong bottle) 
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3.4 Sample Size 
 As for a low prevalence disease, sample size for a desired power is chosen in 
comparing sensitivity of the two tests (MAIPA and MR-MAIPA). The calculation is 
estimated using G*Power software based on paired design of two-sided McNemar’s test. 
Assuming the proportion of discordant pairs of 0.3 and taking the level of significance (alpha 
value) of 0.05 and power of 80%, a total of 44 (40 + 10% drop-out rate) positive samples 
with the disease (by the gold standard) are required to compare sensitivity between the two 
tests.  
Below is the output for the sample size calculation using G*Power: 
Exact - Proportions: Inequality, two independent groups (McNemar)  
Options: α balancing: α/2 on each side, approximation 
Analysis: Sensitivity: Compute required effect size  
Input:   
Tail(s)    = Two 
α err prob   = 0.05 
Power (1-β err prob)  = 0.8 
Total sample size  = 40 
Prop discordant pairs  = 0.3 
The entire sample sent for platelet antibody identification from 1
st
 June 2015 - 30
th
 November 
2015 was taken for this study. 
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3.5 Statistical analysis 
Data analysis was done by using the Statistical Package for the Social Science (IBM® 
SPSS®) version 19. The results of MAIPA and MR-MAIPA will be analyse for sensitivity, 
specificity, positive predictive value and negative predictive value. The descriptive result of 
categorical data presented as frequency/percentage.   
 
3.6 Variables definition 
 
3.6.1  MAIPA 
Monoclonal Antibody Immobilization of Platelet Antigen also known as MAIPA, is a method 
in detecting platelet reactive antibody that was discovered by Kiefel in 1987 (Kiefel et al., 
1987). In this study, MAIPA is considered as the gold standard of the test. 
3.6.2 MR-MAIPA 
Modified Rapid Monoclonal Antibody Immobilization of Platelet Antigen also known as 
MR-MAIPA, is a modification to the original MAIPA in detecting platelet reactive antibody 
that was discovered by Campbell (Campbell et al., 2007). 
3.7 Research tool 
A proforma (MAIPA and MR-MAIPA results) was used to document the antibody detected 
by each method that was used on same sample. A data extraction tool was developed 
according to the research needs. 
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3.8 Ethical Issues 
Ethical approvals were obtained from the Ministry of Health of Malaysia as current study 
involved human blood. Current study  was registered  with the  National  Medical  Research  
Register (NMRR)  with  research  ID number  22920. 
 
3.9  Test procedures 
 
3.9.1 MAIPA 
The MAIPA procedure in this study was based on the working instruction for MAIPA in 
NBCKL (Ibrahim, 2001) 
Day 1  
MAIPA procedure is done within 3 days. The summary of the procedure are as follows. 
Coating Plate 
Microplates were coated with Goat Anti-Mouse antibody (GAM). The coated microplate was 
seal with parafilm and kept in laboratory fridge. The prepared microplates can be used up to 
one week post preparation.  
Designing worksheet 
The worksheet is very important in the procedure. It is where the results are recorded. Basic 
design of the worksheet can be viewed in the appendix section. All samples must be tested in 
duplicate and in parallel with a negative control.  
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Preparation of Platelet Panel Suspension 
Platelet panel was prepared as per working sheet. The panel was from donors whom platelet 
antigens had been genotyped. This will facilitate in the process of identifying the specific 
platelet reactive antibody later in the test. 
Total time used for day 1: The whole day (8 working hours) 
 
Day 2 
Sensitization of platelet 
Sensitization of platelet depends to the working sheet design. This due to the fact that the 
platelet prepared for the test was from donor with already known antigen.  
A 500L of the platelet suspension was dispense into 1.5 ml microtubes which already 
number according to the designed worksheet. These microtubes were then centrifuge for 3 
minutes, resulting formation of platelet pellet at the bottom of the microtubes. The 
supernatant was aspirated and discarded, leaving behind the platelet pellet. 50L PBS/2% 
BSA solution was then added to the platelet pellet in the microtubes. 120l of patient’s serum 
(investigated serum) was later added and incubated at 37
o
C for 30 minutes. Incubation period 
may be prolonged to maximum of one hour. After incubation, the mixture was washed using 
750L cold NaCl/0.2%/BSA and 50L. After washing, Monoclonal Antibody was added 
(according to the designed worksheet). The platelet was then incubated again at 37
o
C for 30 
minutes. Post incubation, the platelet was washed twice with 750l cold NaCl/0.2%/BSA 
solution and centrifuge for 3 minutes. The supernatant was aspirated and discarded, leaving 
behind sensitized platelet pellet which already forming trimetric complex (Platelet reactive 
antibody-platelet antigen-Murine monoclonal antibody).  
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Solubilisation of platelet   
The sensitized platelet pellet was ready for solubilisation in order to free the trimeric complex 
to be captured by GAM later in the process.  A 50l of cold solubilisation buffer was added 
to the sensitized platelet pellet and incubated at 4ºC for 30 minutes. After incubation, the 
microtubes were centrifuged for 30 minutes at 4ºC. During the incubation period earlier, 
blocking GAM plate was done.  
 
Blocking GAM plate 
The GAM coated plate that was prepared in Day 1 was taken out of the fridge and washed for 
5 times with cold ELISA wash buffer. After washing, 300L MAIPA wash buffer/0.2% BSA 
was added to each well. The GAM plate was then incubated at 4ºC for 60 minutes. During the 
incubation, new 0.8mL microtubes were labelled and filled with 150L MAIPA wash 
buffer/0.2%BSA . These microtubes later were use in the following step. 
 
Capture of Antibody Coated GP 
The GAM coated microplate that was incubated earlier was removed from the fridge, drained 
and dried thoroughly. 
The solubilised platelet in earlier step was retrieved post centrifugation. The supernatant 
(platelet lysate) was aspirated and transferred approximately 50L into newly labelled 0.8mL 
microtubes that had been prepared earlier. It was then mixed well. After mixing, 
approximately 50L of the diluted lysate was transferred into the GAM microplate. 50L of 
cold MAIPA wash buffer 0.2% BSA was then added into the microplate. The microplate was 
then incubated overnight at 4ºC.  
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If there was urgency, the microplate incubation period may be shorten to 2 hours then 
followed with ELISA assay which is usually done in Day 3 of the test. 
Total time taken for Day 2 procedure is approximately the whole day, including the overnight 
incubation period. However, it maybe shorten to approximately 6 to 7 hours if the incubation 
step is shorten to 2 hours only. 
 
Day 3 
 ELISA Assay 
This procedure was carried out after overnight incubation of the GAM plate earlier in Day 2 
or after a period of 2 hours incubation in urgent cases.  
The Goat Anti Human IgG/IgM (GAH-G/GAH-M) was prepared. The microplate that was 
incubated earlier was retrieved drained, followed by five times washing with ELISA wash 
buffer. After washing, the GAH was added to the microplate. The plate incubated in the 
laboratory fridge for 2 hours. Post incubation, substrate was added to the plate, which will 
change in colour if the trimetric complex was present. The result is read at 405nm light 
absorbance, at 15 minutes interval, up to 60 minutes.  The final result (at 60 minutes) was 
then recorded on the MAIPA working sheet. 
The total time taken for Day 3 is approximately 4 hours. 
As seen in the description of the test above, the MAIPA can be shorten to 2 days or even a 
day. These depends on the preparation of the GAM plate (as described in Day 1) and 
incubation of the captured of antibody coated GP (as described in Day 2). The test can be 
shorten to two working days provided the GAM plate was prepared in Day One and to 
proceed with the rest of the procedure in Day Two, in which the incubation of the captured of 
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antibody coated GP is shorten to 2 hours. The MAIPA procedure can be further shorten to a 
day provided that the GAM plate had been prepared much more earlier prior to the procedure 
day as the coated GAM plate can be kept up to a week after its preparation. 
 
3.9.2 MR-MAIPA Procedure 
  The Modified Rapid MAIPA (MR-MAIPA) was first used in NBCKL since 2013. By 
using the MR-MAIPA, the test duration is shorten to 1 day, compared to previously that was 
3 days. The NBCKL MR-MAIPA method is based on the work of Campbell and colleagues, 
A Modified fast MAIPA for the detection of HPA platelet antigen antibodies: a multi-centre 
evaluation of a rapid monoclonal antibody specific immobilisation of platelet antigen 
(MAIPA) assay, which was published in the Vox Sanguinis 2007 (Campbell et al., 2007). 
The MR-MAIPA used the same principle as MAIPA. The outlines of the MR-MAIPA are as 
follows: 
1. Preparation of Coated Flat-Well (F-Well) Microplate 
 A 100L of GAM was added to each well according to designed worksheet. The coated F-
well plate is incubated at 4ºC for at least 3 hours. The prepared microplate can be stored up to 
2 weeks at 4ºC. 
 
2. Incubation of Platelets with serum 
A 100L of donor platelets was used per well of U well microtitre plate. The U-well 
microtitre plate was then centrifuge for 3 minutes. The supernatant was discarded, leaving 
behind the platelet pellet. The U-well microplate was dried on paper towel. After the 
microtitre plate had dried, 50L of TBS/BSA was added to each well, resulting in 
